All In Biotech

Drug Trial Radar · NCT04875702

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout: A Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 650 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

650

Planned (sponsor's estimate)

Start

Feb 22, 2024

Primary completion

Sep 1, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted
May 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TRUST study is a randomized, controlled multicenter study to evaluate the management of gout by comparing two commonly used treatment strategies for gout (TTT vs TTASx) to determine the most beneficial for a patient-centered gout outcomes, as well as relevant cardiovascular-metabolic-renal endpoints.

Conditions

  • Gout

Interventions

  • AllopurinolDrug

    For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target. For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.

  • Naproxen 250 MGDrug

    Naproxen 250 mg p.o. twice daily

  • Colchicine 0.6 mgDrug

    Colchicine 0.6 mg p.o. once daily

  • Colchicine 1.2 mgDrug

    Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.

  • Naproxen 500 MgDrug

    dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.

  • Prednisone 40 mgDrug

    For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of gout flareTime frame: baseline to two years of follow up

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • The University of Alabama at Birmingham

    Birmingham, Alabama · Not yet recruiting

  • UCLA Health

    Santa Monica, California · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital (BWH)

    Boston, Massachusetts · Recruiting

  • Boston Medical Center (BMC)

    Boston, Massachusetts · Not yet recruiting

  • NYU Langone

    New York, New York · Recruiting

  • West Virginia University (Including Mobile Clinical Trials Unit)

    Morgantown, West Virginia · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.